NCT05657925View on ClinicalTrials.gov

Study of Ondansetron in the Prevention of Sleep Syncope: The Nineth Prevention of Syncope Trial (POST9)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Sleep Syncope
Interventions
DRUG

ondansetron 8 mg

Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.

DRUG

Matching placebo

Matching placebo will be identical in appearance to the active treatment pill

Trial Locations (1)

T2N 1N4

University of Calgary, Calgary

All Listed Sponsors
lead

University of Calgary

OTHER